Send to

Choose Destination
Cardiovasc Res. 2016 Jul 15;111(2):154-62. doi: 10.1093/cvr/cvw107. Epub 2016 Jun 13.

Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.

Author information

Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria
Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.


The second messenger cyclic guanosine 3'5' monophosphate (cGMP) and its downstream effector protein kinase G (PKG) have been discovered more than 40 years ago. In vessels, PKG1 induces smooth muscle relaxation in response to nitric oxide signalling and thus lowers systemic and pulmonary blood pressure. In platelets, PKG1 stimulation by cGMP inhibits activation and aggregation, and in experimental models of heart failure (HF), PKG1 activation by inhibiting cGMP degradation is protective. The net effect of the above-mentioned signalling is cardiovascular protection. Yet, while modulation of cGMP-PKG has entered clinical practice for treating pulmonary hypertension or erectile dysfunction, translation of promising studies in experimental HF to clinical success has failed thus far. With the advent of new technologies, novel mechanisms of PKG regulation, including mechanosensing, redox regulation, protein quality control, and cGMP degradation, have been discovered. These novel, non-canonical roles of PKG1 may help understand why clinical translation has disappointed thus far. Addressing them appears to be a requisite for future, successful translation of experimental studies to the clinical arena.


Cardiac mechanosensing; Phosphodiesterase; Proteasome; Protein kinase G; Redox regulation; cGMP-dependent protein kinase type 1

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center